

Porton Advanced and Genesee Biotech focus on advancing circRNA innovative therapeutics in China

31 July 2024 | News

CircRNA to be the next-generation RNA platform for vaccines, rare disease therapies, and anti-tumour therapies



Porton Advanced Solutions, a subsidiary of the globally recognised contract development and manufacturing organisation (CDMO) Porton Pharma Solutions, has reached a strategic cooperation with Guangzhou Genesee Biotech Co. Both sides will combine their respective strengths in the field of gene therapy to jointly provide better drug development services.

Leveraging Porton Advanced's end-to-end cell and gene therapy CDMO service platform and resource advantages, combined with Genesee Biotech's comprehensive core patented technologies in circRNA drug concept validation and process development, the two companies will jointly propel technological innovation and clinical translation, thereby accelerating the implementation of innovative circRNA therapies.

Porton Advanced can provide comprehensive CMC services from preclinical to clinical production. Genesee Biotech, relying on its profound technology and robust original R&D capability, has broken through the technical bottleneck of circRNA drug development and possesses independent intellectual property rights over its core circularisation technology.

In this cooperation, both parties will establish a comprehensive strategic partnership to deeply expanding technological cooperation and resource sharing in the field of circRNA. This will further strengthen Porton Advanced's end-to-end CDMO platform, from innovation in research and technology to high-quality project delivery, thereby providing more valuable services to customers.